Indeed, current guidelines recommend that children with DMD should start on RAAS inhibition (including AT1R blockers (ARBs), and ACEI) by age 10 or earlier if myocardial dysfunction is detected [44]. This evidence concerns the gene AGTR1 and Duchenne muscular dystrophy.